Form 4: Vir Biotechnology Director Charles Elliott Sigal Reports Transactions

Director Charles Elliott Sigal reports acquisition of shares and stock options in Vir Biotechnology, along with disposal of shares.

Summary

• On May 30, 2024, Charles Elliott Sigal, a director of Vir Biotechnology, Inc., reported several transactions.
• Sigal acquired 8,000 shares of common stock at $0 and 16,000 stock options with an exercise price of $10.39.
• The stock options are exercisable from May 30, 2025, to May 29, 2034.
• Sigal also disposed of 10,000 shares of common stock held indirectly through Sigal Family Investments, LLC.
• Following these transactions, Sigal directly owns 23,806 shares and 16,000 stock options.
• Sigal disclaims beneficial ownership of the securities held by Sigal Family Investments, LLC, except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The director acquired shares and options, indicating confidence, but also disposed of shares, which could raise concerns. The overall impact is likely to be minimal.

Positives

• Acquisition of 8,000 shares by a director may signal confidence in the company's future.
• The grant of 16,000 stock options to the director aligns his interests with the long-term success of the company.

Negatives

• The disposal of 10,000 shares, even if indirect, could be interpreted negatively by some investors.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future performance.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares and options as a positive signal.
• The disposal of shares, even if indirect, could create some uncertainty among shareholders.

Key Dates